Maghnite: novel inorganic reinforcement for single-step synthesis of PDMS nanocomposites with improved thermal, mechanical and textural properties

Kherroub, Djamal Eddine; Boulaouche, Tarik

doi:10.1007/s11164-020-04257-x

Cited by 16 publications

(4 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is because both porous and non-porous PDMS were formed of the same components, with the exception that sugar was used to generate pores in the porous PDMS, which was entirely leached out of the substance during the soaking times. The PDMS curve shown in this work is comparable to that described in other investigations 33 – 36 . Both porous and non-porous PDMS degraded thermally more slowly over a larger temperature range, with the initial breakdown temperature rising as the temperature rose.…”

Section: Resultssupporting

confidence: 89%

In-vivo studies of targeted and localized cancer drug release from microporous poly-di-methyl-siloxane (PDMS) devices for the treatment of triple negative breast cancer

Eluu,

Obayemi,

Salifu

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Triple-negative breast cancer (TNBC) treatment is challenging and frequently characterized by an aggressive phenotype and low prognosis in comparison to other subtypes. This paper presents fabricated implantable drug-loaded microporous poly-di-methyl-siloxane (PDMS) devices for the delivery of targeted therapeutic agents [Luteinizing Hormone-Releasing Hormone conjugated paclitaxel (PTX-LHRH) and Luteinizing Hormone-Releasing Hormone conjugated prodigiosin (PG-LHRH)] for the treatment and possible prevention of triple-negative cancer recurrence. In vitro assessment using the Alamar blue assay demonstrated a significant reduction (p < 0.05) in percentage of cell growth in a time-dependent manner in the groups treated with PG, PG-LHRH, PTX, and PTX-LHRH. Subcutaneous triple-negative xenograft breast tumors were then induced in athymic female nude mice that were four weeks old. Two weeks later, the tumors were surgically but partially removed, and the device implanted. Mice were observed for tumor regrowth and organ toxicity. The animal study revealed that there was no tumor regrowth, six weeks post-treatment, when the LHRH targeted drugs (LHRH-PTX and LHRH-PGS) were used for the treatment. The possible cytotoxic effects of the released drugs on the liver, kidney, and lung are assessed using quantitative biochemical assay from blood samples of the treatment groups. Ex vivo histopathological results from organ tissues showed that the targeted cancer drugs released from the implantable drug-loaded device did not induce any adverse effect on the liver, kidneys, or lungs, based on the results of qualitative toxicity studies. The implications of the results are discussed for the targeted and localized treatment of triple negative breast cancer.

show abstract

Section: Resultssupporting

confidence: 89%

In-vivo studies of targeted and localized cancer drug release from microporous poly-di-methyl-siloxane (PDMS) devices for the treatment of triple negative breast cancer

Eluu,

Obayemi,

Salifu

et al. 2024

Sci Rep

View full text Add to dashboard Cite

show abstract

“…This is because both porous and non-porous PDMS were formed of the same components, with the exception that sugar was used to generate pores in the porous PDMS, which was entirely leached out of the substance during the soaking times. The PDMS curve shown in this work is comparable to that described in other investigations [33][34][35][36] . Both porous and non-porous PDMS degraded thermally more slowly over a larger temperature range, with the initial breakdown temperature rising as the temperature rises.…”

Section: Thermo-gravimetric Analysis Of Pdms-based Substratessupporting

confidence: 89%

Targeted and Localized Cancer Drug Release Kinetics from Microporous Poly-di-methyl-siloxane (PDMS) Devices: in-vivo Studies for the Treatment of Triple Negative Breast Cancer

Eluu,

Yiporo,

Salifu

et al. 2023

Preprint

View full text Add to dashboard Cite

Triple-negative breast cancer (TNBC) treatment is challenging and frequently characterized by an aggressive phenotype and low prognosis in comparison to other subtypes. This paper presents an implantable microporous poly-di-methyl-siloxane device for the delivery of targeted therapeutic agents (LHRH-paclitaxel and LHRH-prodigiosin) for the treatment and possible prevention of triple-negative cancer recurrence. The possible cytotoxic effects of the drugs on liver, kidney, and lung tissues are also assessed. Drug-loaded implantable microporous poly-di-methyl-siloxane (PDMS) devices were fabricated. Subcutaneous triple-negative xenograft breast tumors were then induced in athymic female nude mice that were four weeks old. Two weeks later, the tumors were surgically removed, and the device implanted. Mice were observed for tumor regrowth and organ toxicity. In addition, the cytotoxic response was assessed in vitro using the Alamar blue assay. The animal study revealed that there was no tumor regrowth, six weeks post-treatment, when the LHRH targeted drugs (LHRH-paclitaxel and LHRH-prodigiosin) were used for the treatment. It was also noted that the targeted cancer drugs did not induce any adverse effect on the liver, kidneys, or lungs, based on the results of the quantitative and qualitative toxicity studies. Furthermore, the outcomes of the in vitro assessment demonstrated a significant reduction (P < 0.05) in percentage cell growth inhibition in a time-dependent manner in the groups treated with PG, PG-LHRH, PTX, and PTX-LHRH. The implications of the results are discussed for the targeted and localized treatment of triple negative breast cancer.

show abstract

“…58 Above 400 C, it can be observed that the temperatures of initial decomposition for the nanocomposites shifts to higher values compared with pure PDMS, which indicates the presence of magnetite as a filler enhances the thermal stability of the PDMS matrix in PDMS nanocomposites. According to several authors [58][59][60] this degradation is due to the phenomenon of depolymerization around 400-600 C.…”

Section: Thermal Propertiesmentioning

confidence: 99%

Mechanical and thermal properties of polydimethylsiloxane/magnetite nanocomposites for cancer treatment by localized hyperthermia and photothermal ablation

Onyekanne

Oyewole

Salifu

et al. 2022

J of Applied Polymer Sci

View full text Add to dashboard Cite

A combination of experiments and theoretical models is used to study the mechanical and thermal properties of polydimethylsiloxane (PDMS) and magnetite nanoparticle‐reinforced PDMS composites with the potential for applications in biomedical implants for localized hyperthermia and photothermal ablation. Composite samples with varying weight fractions (0,1, 5, and 10 wt.%) of Fe3O4 nanoparticles were fabricated and tested to determine their stress–strain behavior and fracture toughness. The measured mechanical properties are also compared with predictions from composite and toughening models. The implications of the results are discussed for the design of plasmonic/magnetic nanocomposites with attractive combinations of mechanical and thermal properties that are relevant to laser hyperthermia and photo‐thermal‐ablation.

show abstract

Maghnite: novel inorganic reinforcement for single-step synthesis of PDMS nanocomposites with improved thermal, mechanical and textural properties

Cited by 16 publications

References 49 publications

In-vivo studies of targeted and localized cancer drug release from microporous poly-di-methyl-siloxane (PDMS) devices for the treatment of triple negative breast cancer

In-vivo studies of targeted and localized cancer drug release from microporous poly-di-methyl-siloxane (PDMS) devices for the treatment of triple negative breast cancer

Targeted and Localized Cancer Drug Release Kinetics from Microporous Poly-di-methyl-siloxane (PDMS) Devices: in-vivo Studies for the Treatment of Triple Negative Breast Cancer

Mechanical and thermal properties of polydimethylsiloxane/magnetite nanocomposites for cancer treatment by localized hyperthermia and photothermal ablation

Contact Info

Product

Resources

About